Mustophoran (Fotemustine)

Fotemustine, the active ingredient in Mustophoran, is a nitrosourea alkylating agent presented as a sterile solution for injection for intravenous use. It is employed in the treatment of metastatic melanoma and high‑grade brain tumors such as glioblastoma, providing cytotoxic activity against rapidly dividing cancer cells in adult patients. It is indicated for patients with advanced disease where conventional therapies have limited efficacy.

GNH USA supplies Mustophoran as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and specialty pharmacies worldwide, ensuring quality‑controlled sourcing and regulatory compliance for clinical use and supports clinical trial participation.

Fotemustine is used in oncology for the treatment of malignant melanoma and primary brain tumors.

Metastatic melanoma: prolongs progression‑free survival in patients with unresectable disease. Glioblastoma: provides cytotoxic effect to reduce tumor burden. Primary brain tumors (e.g., anaplastic astrocytoma): contributes to disease control when combined with radiotherapy.

Fotemustine may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting. - Fatigue and general weakness. - Myelosuppression manifested as leukopenia or thrombocytopenia. - Alopecia (hair loss). - Transient elevation of liver enzymes.

Serious or Rare Side Effects: - Pulmonary fibrosis. - Severe or opportunistic infections. - Hemorrhagic cystitis. - Delayed bone‑marrow failure. - Anaphylactic or hypersensitivity reactions. - Renal toxicity.

Before initiating Mustophoran therapy, several safety measures should be observed. - Baseline assessment: perform complete blood count and liver function tests prior to the first dose. - Monitoring: repeat hematology and biochemistry weekly during treatment. - Renal function: assess creatinine clearance because of potential nephrotoxicity. - Pregnancy and lactation: avoid use; the drug may cause fetal harm. - Concomitant myelosuppressive agents: use with caution to prevent additive bone‑marrow suppression. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Fotemustine can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Other alkylating or cytotoxic agents: may cause excessive myelosuppression. - Live vaccines: increased risk of infection due to immunosuppression. - Anticoagulants: heightened bleeding risk because of thrombocytopenia. - Strong enzyme inducers: may reduce drug exposure.

Moderate Interactions (Monitor Closely): - Radiation therapy: enhanced tissue toxicity when given concurrently. - Immunosuppressants: increased susceptibility to infections. - Nephrotoxic drugs: potential additive renal impairment.